180 results
Page 3 of 9
8-K
EX-10.1
n3e9u8fgyktua0au
9 Dec 20
Other Events
9:03am
8-K
EX-10.2
rv7mmb8kbkl5 nha8
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-10.1
dg20a7h
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K/A
EX-10.5
sc801 jlnqsy
1 Oct 20
Departure of Directors or Certain Officers
4:17pm
8-K
EX-10.2
l97o1i
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
9to xdht8r02kqtea4
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.4
sapgkj
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.5
u4r6n53ozs8z8su9
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.3
13azx2f2i944hxsi
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
65lm ohe4i1r8sfx
19 Jun 20
Departure of Directors or Certain Officers
4:16pm
8-K
EX-10.1
jl1qp7b4vn q3h
27 Apr 20
Entry into a Material Definitive Agreement
4:18pm